A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment

Abstract Many recent studies have investigated the role of either Chloroquine (CQ) or Hydroxychloroquine (HCQ) alone or in combination with azithromycin (AZM) in the management of the emerging coronavirus. This systematic review and meta-analysis of either published or preprint observational studies...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ramy Mohamed Ghazy, Abdallah Almaghraby, Ramy Shaaban, Ahmed Kamal, Hatem Beshir, Amr Moursi, Ahmed Ramadan, Sarah Hamed N. Taha
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/ecd04232fe1149fcb1b3c29fb71761ff
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ecd04232fe1149fcb1b3c29fb71761ff
record_format	dspace
spelling	oai:doaj.org-article:ecd04232fe1149fcb1b3c29fb71761ff2021-12-02T13:58:14ZA systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment10.1038/s41598-020-77748-x2045-2322https://doaj.org/article/ecd04232fe1149fcb1b3c29fb71761ff2020-12-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-77748-xhttps://doaj.org/toc/2045-2322Abstract Many recent studies have investigated the role of either Chloroquine (CQ) or Hydroxychloroquine (HCQ) alone or in combination with azithromycin (AZM) in the management of the emerging coronavirus. This systematic review and meta-analysis of either published or preprint observational studies or randomized control trials (RCT) aimed to assess mortality rate, duration of hospital stay, need for mechanical ventilation (MV), virologic cure rate (VQR), time to a negative viral polymerase chain reaction (PCR), radiological progression, experiencing drug side effects, and clinical worsening. A search of the online database through June 2020 was performed and examined the reference lists of pertinent articles for in-vivo studies only. Pooled relative risks (RRs), standard mean differences of 95% confidence intervals (CIs) were calculated with the random-effects model. Mortality was not different between the standard care (SC) and HCQ groups (RR = 0.99, 95% CI 0.61–1.59, I2 = 82%), meta-regression analysis proved that mortality was significantly different across the studies from different countries. However, mortality among the HCQ + AZM was significantly higher than among the SC (RR = 1.8, 95% CI 1.19–2.27, I2 = 70%). The duration of hospital stay in days was shorter in the SC in comparison with the HCQ group (standard mean difference = 0.57, 95% CI 0.20–0.94, I2 = 92%), or the HCQ + AZM (standard mean difference = 0.77, 95% CI 0.46–1.08, I2 = 81). Overall VQR, and that at days 4, 10, and 14 among patients exposed to HCQ did not differ significantly from the SC [(RR = 0.92, 95% CI 0.69–1.23, I2 = 67%), (RR = 1.11, 95% CI 0.26–4.69, I2 = 85%), (RR = 1.21, 95% CI 0.70–2.01, I2 = 95%), and (RR = 0.98, 95% CI 0.76–1.27, I2 = 85% )] respectively. Exposure to HCQ + AZM did not improve the VQR as well (RR = 3.23, 95% CI 0.70–14.97, I2 = 58%). The need for MV was not significantly different between the SC and HCQ (RR = 1.5, 95% CI 0.78–2.89, I2 = 81%), or HCQ + AZM (RR = 1.27, 95% CI 0.7–2.13, I2 = 88%). Side effects were more reported in the HCQ group than in the SC (RR = 3.14, 95% CI 1.58–6.24, I2 = 0). Radiological improvement and clinical worsening were not statistically different between HCQ and SC [(RR = 1.11, 95% CI 0.74–1.65, I2 = 45%) and (RR = 1.28, 95% CI 0.33–4.99), I2 = 54%] respectively. Despite the scarcity of published data of good quality, the effectiveness and safety of either HCQ alone or in combination with AZM in treating COVID-19 cannot be assured. Future high-quality RCTs need to be carried out. PROSPERO registration: CRD42020192084.Ramy Mohamed GhazyAbdallah AlmaghrabyRamy ShaabanAhmed KamalHatem BeshirAmr MoursiAhmed RamadanSarah Hamed N. TahaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-18 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Ramy Mohamed Ghazy Abdallah Almaghraby Ramy Shaaban Ahmed Kamal Hatem Beshir Amr Moursi Ahmed Ramadan Sarah Hamed N. Taha A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment
description	Abstract Many recent studies have investigated the role of either Chloroquine (CQ) or Hydroxychloroquine (HCQ) alone or in combination with azithromycin (AZM) in the management of the emerging coronavirus. This systematic review and meta-analysis of either published or preprint observational studies or randomized control trials (RCT) aimed to assess mortality rate, duration of hospital stay, need for mechanical ventilation (MV), virologic cure rate (VQR), time to a negative viral polymerase chain reaction (PCR), radiological progression, experiencing drug side effects, and clinical worsening. A search of the online database through June 2020 was performed and examined the reference lists of pertinent articles for in-vivo studies only. Pooled relative risks (RRs), standard mean differences of 95% confidence intervals (CIs) were calculated with the random-effects model. Mortality was not different between the standard care (SC) and HCQ groups (RR = 0.99, 95% CI 0.61–1.59, I2 = 82%), meta-regression analysis proved that mortality was significantly different across the studies from different countries. However, mortality among the HCQ + AZM was significantly higher than among the SC (RR = 1.8, 95% CI 1.19–2.27, I2 = 70%). The duration of hospital stay in days was shorter in the SC in comparison with the HCQ group (standard mean difference = 0.57, 95% CI 0.20–0.94, I2 = 92%), or the HCQ + AZM (standard mean difference = 0.77, 95% CI 0.46–1.08, I2 = 81). Overall VQR, and that at days 4, 10, and 14 among patients exposed to HCQ did not differ significantly from the SC [(RR = 0.92, 95% CI 0.69–1.23, I2 = 67%), (RR = 1.11, 95% CI 0.26–4.69, I2 = 85%), (RR = 1.21, 95% CI 0.70–2.01, I2 = 95%), and (RR = 0.98, 95% CI 0.76–1.27, I2 = 85% )] respectively. Exposure to HCQ + AZM did not improve the VQR as well (RR = 3.23, 95% CI 0.70–14.97, I2 = 58%). The need for MV was not significantly different between the SC and HCQ (RR = 1.5, 95% CI 0.78–2.89, I2 = 81%), or HCQ + AZM (RR = 1.27, 95% CI 0.7–2.13, I2 = 88%). Side effects were more reported in the HCQ group than in the SC (RR = 3.14, 95% CI 1.58–6.24, I2 = 0). Radiological improvement and clinical worsening were not statistically different between HCQ and SC [(RR = 1.11, 95% CI 0.74–1.65, I2 = 45%) and (RR = 1.28, 95% CI 0.33–4.99), I2 = 54%] respectively. Despite the scarcity of published data of good quality, the effectiveness and safety of either HCQ alone or in combination with AZM in treating COVID-19 cannot be assured. Future high-quality RCTs need to be carried out. PROSPERO registration: CRD42020192084.
format	article
author	Ramy Mohamed Ghazy Abdallah Almaghraby Ramy Shaaban Ahmed Kamal Hatem Beshir Amr Moursi Ahmed Ramadan Sarah Hamed N. Taha
author_facet	Ramy Mohamed Ghazy Abdallah Almaghraby Ramy Shaaban Ahmed Kamal Hatem Beshir Amr Moursi Ahmed Ramadan Sarah Hamed N. Taha
author_sort	Ramy Mohamed Ghazy
title	A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment
title_short	A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment
title_full	A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment
title_fullStr	A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment
title_full_unstemmed	A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment
title_sort	systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in covid-19 treatment
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/ecd04232fe1149fcb1b3c29fb71761ff
work_keys_str_mv	AT ramymohamedghazy asystematicreviewandmetaanalysisonchloroquineandhydroxychloroquineasmonotherapyorcombinedwithazithromycinincovid19treatment AT abdallahalmaghraby asystematicreviewandmetaanalysisonchloroquineandhydroxychloroquineasmonotherapyorcombinedwithazithromycinincovid19treatment AT ramyshaaban asystematicreviewandmetaanalysisonchloroquineandhydroxychloroquineasmonotherapyorcombinedwithazithromycinincovid19treatment AT ahmedkamal asystematicreviewandmetaanalysisonchloroquineandhydroxychloroquineasmonotherapyorcombinedwithazithromycinincovid19treatment AT hatembeshir asystematicreviewandmetaanalysisonchloroquineandhydroxychloroquineasmonotherapyorcombinedwithazithromycinincovid19treatment AT amrmoursi asystematicreviewandmetaanalysisonchloroquineandhydroxychloroquineasmonotherapyorcombinedwithazithromycinincovid19treatment AT ahmedramadan asystematicreviewandmetaanalysisonchloroquineandhydroxychloroquineasmonotherapyorcombinedwithazithromycinincovid19treatment AT sarahhamedntaha asystematicreviewandmetaanalysisonchloroquineandhydroxychloroquineasmonotherapyorcombinedwithazithromycinincovid19treatment AT ramymohamedghazy systematicreviewandmetaanalysisonchloroquineandhydroxychloroquineasmonotherapyorcombinedwithazithromycinincovid19treatment AT abdallahalmaghraby systematicreviewandmetaanalysisonchloroquineandhydroxychloroquineasmonotherapyorcombinedwithazithromycinincovid19treatment AT ramyshaaban systematicreviewandmetaanalysisonchloroquineandhydroxychloroquineasmonotherapyorcombinedwithazithromycinincovid19treatment AT ahmedkamal systematicreviewandmetaanalysisonchloroquineandhydroxychloroquineasmonotherapyorcombinedwithazithromycinincovid19treatment AT hatembeshir systematicreviewandmetaanalysisonchloroquineandhydroxychloroquineasmonotherapyorcombinedwithazithromycinincovid19treatment AT amrmoursi systematicreviewandmetaanalysisonchloroquineandhydroxychloroquineasmonotherapyorcombinedwithazithromycinincovid19treatment AT ahmedramadan systematicreviewandmetaanalysisonchloroquineandhydroxychloroquineasmonotherapyorcombinedwithazithromycinincovid19treatment AT sarahhamedntaha systematicreviewandmetaanalysisonchloroquineandhydroxychloroquineasmonotherapyorcombinedwithazithromycinincovid19treatment
_version_	1718392235636031488

A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment

Ejemplares similares